|
|
Stakeholder Opinions: HIV - Reaching the 'Untapped' Patient PopulationPublished by: Datamonitor Published: Nov. 13, 2003 - 76 Pages Table of ContentsTABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 3 Scope of the analysis 3 Datamonitor insight into the disease HIV and AIDS ‘untapped’ markets 4 Estimated US figures for prevalence of total HIV and AIDS cases reveals a sector of 637,553 patients currently untreated (56.5%). Assuming 100% access and current treatment costs, this equates to an annual cumulative revenue loss of approximately $6.3bn (2002), a figure projected to accumulate to $12.2bn by 2010. Even gaining a small percentage of this large untapped market would lift current market value significantly. 4 Untapping patient potential will require companies to more actively address issues surrounding low rates of presentation and diagnosis. These areas of intervention are highly interdependant, presenting as a multifaceted challenge. Companies need to balance carefully their investment in funding certain initiatives against potential increases in revenue. 5 Diagnostic and monitoring tools, essential to treating existing and potential HIV patients vary widely in terms of cost, accuracy, ease and speed of use. In addition, the use of genotypic and phenotypic resistance testing to improve patient compliance is increasing. Datamonitor believes that underlying positive commercial drivers within these sectors will further ease access to the ‘untapped’ pool. 6 For potential collaboration, therapeutic companies should formulate clear objectives for both the public and the private sector. Public sector based initiatives include partnerships with governments, international bodies and patients, physicians and advocacy groups. Private sector based collaborations, specifically with HIV diagnostic companies focus on gaining access to latest technology but also the maintenance of market presence. 7 Summary 9 Key metrics 10 CHAPTER 2 QUANTIFYING UNTAPPED PATIENT POPULATIONS 16 The opportunity 16 Untapped HIV patient population in the US market 18 Untapped HIV patient population in the European market 21 Western Europe 22 Eastern Europe 23 Central Europe 24 Summary 24 Other regions 25 Post diagnosis: the untreated sector 25 CHAPTER 3 LIMITS TO PATIENT POTENTIAL 29 Factors affecting diagnosis of HIV 29 Presentation 30 Lifestyle and awareness 30 Education and perception of general public 32 Case study: UK 33 IDUs and needle exchange programs 34 MSM transmission 35 Heterosexual transmission 35 Other routes of transmission 35 Education and perception of physicians 36 Healthcare infrastructure and resources 37 Screening 37 Screening of high-risk individuals 38 Screening of pregnant women 39 Diagnosis 41 Treatment 41 Compliance to HIV therapy 41 Current compliance rates 42 Treatment eligibility 44 CHAPTER 4 DIAGNOSTICS AND MONITORING 45 Market overview 45 Key diagnostic and resistance tests 46 Diagnostic tests 47 Antibody testing 47 Antigen detection 49 Home diagnostic kits 50 Summary 51 Resistance testing 52 Phenotypic resistance tests 52 Genotypic resistance tests 53 CHAPTER 5 STRATEGIC PARTNERSHIPS 55 Partnerships with the public sector 55 Governments in the major markets 55 Case study: Abbott 57 Supranational organizations 57 Access to HIV diagnostics 57 Patients, physicians and advocacy groups 58 The tools of mass media 59 Case study: Schering-Plough 59 Raising compliance 60 Identification through treatment of comorbidities 61 Case study: GSK 62 Partnerships with other companies 62 Therapy-therapy collaborations 63 Therapy-diagnostic collaborations 63 Summary 64 APPENDIX A 65 List of tables 65 List of figures 65 Websites 68 Company websites 69 APPENDIX B 70 About Datamonitor 70 About Datamonitor Healthcare 70 Datamonitor Healthcare’s research and analysis methodologies 71 Datamonitor Healthcare’s therapy area capabilities 71 About the Infectious Disease analysis team 72 Datamonitor Healthcare’s Consulting expertise 73 Datamonitor’s Therapeutic Consulting expertise 74 Key therapy team members 75 John Savopoulos, Lead Analyst, Infectious Diseases 75 David Abramson, Therapeutic Lead Consultant 75 Disclaimer 76 AbstractIntroductionIn 2002, global estimates of HIV/AIDS cases were 42 million (UNAIDS, 2002). Datamonitor believes that approximately 50% are undiagnosed and untreated - this represents a significant commercial opportunity for the pharma industry. Scope Key data and epidemiology of the seven major HIV therapeutic markets highlighting untreated ‘untapped’ population Overview of the limitations surrounding ‘untapping’ patient potential discussing issues such as patient presentation, screening and diagnosis Examination of a number of diagnostic and monitoring tools that vary in terms of ease of use, cost and accuracy Discussion of comprehensive initiatives for HIV therapeutic companies in both the public and private sector, based on key opinion leader interviews Report Highlights In all seven of the major HIV therapeutic markets, a significant proportion of the HIV and AIDS patient population ‘escapes’ diagnosis and subsequent treatment. Companies need to be aware of this significant ‘untapped’ population in both existing and emergent markets. Presentation and diagnosis are two key areas that have been identified for HIV therapeutic stakeholders to focus on, especially, in regards to the latter, in light of the growth of the molecular diagnostic market for all areas of infectious diseases. Pharma companies looking to capture the untreated HIV population need to target both the public and private sectors. Public sector initiatives include partnerships with governments, international bodies and with patients, physicians and advocacy groups. Private sector collaborations, specifically with HIV diagnostic companies, should be nurtured. Reasons to Purchase Awareness of the sheer volume of the ‘untapped’ HIV population will confer an advantage to the key players in the HIV therapy and diagnostic sectors. Provides an insight into the HIV diagnostic and monitoring tools on the market, with a thorough discussion of their limitations and advantages. Presents comprehensive strategic recommendations with which to reach this untreated ‘untapped’ market. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||